Format

Send to

Choose Destination
Eur J Dermatol. 2015 Jul-Aug;25(4):290-5. doi: 10.1684/ejd.2015.2547.

Towards a specific marker for acute bradykinin-mediated angioedema attacks: a literature review.

Author information

1
Internal Medicine Department,, Centre national de référence des angiœdèmes (CREAK).
2
Universités des Alpes-Grenoble 1, 38041 Grenoble, France, CEA, DSV/iRTSV,, INSERM, Unité 1036, Biologie du cancer et de l'infection, 17, rue des Martyrs, 38054 Grenoble, France.
3
Centre national de référence des angiœdèmes (CREAK),, Universités des Alpes-Grenoble 1, 38041 Grenoble, France, Immunology Department, Grenoble University Hospital, 38000 Grenoble, France.
4
Internal Medicine Department,, Centre national de référence des angiœdèmes (CREAK),, Universités des Alpes-Grenoble 1, 38041 Grenoble, France, CEA, DSV/iRTSV,, INSERM, Unité 1036, Biologie du cancer et de l'infection, 17, rue des Martyrs, 38054 Grenoble, France.

Abstract

BACKGROUND:

Bradykinin-mediated angioedema (AE) is a rare disease characterised by recurrent angioedema linked to acquired (e.g. angiotensin converting enzyme inhibitor induced AE) or hereditary disorders (e.g. AE type I or II). As the clinical picture can be misleading, diagnosis of this disease is sometimes difficult. A bradykinin-mediated AE attack may be a therapeutic emergency which requires access to effective, but expensive, treatments. Their prescription must therefore be justified. No specific marker of acute bradykinin-mediated AE attacks has yet been identified to facilitate the therapeutic decision but it has been sought in many studies.

PURPOSE:

This article reviews the literature on this type of biomarker, comparing candidate bradykinin-mediated AE markers to candidate markers of mast cell activation.

CONCLUSION:

The most interesting biomarkers are those linked to endothelial stress (VE cadherin, E-selectin, endothelin-1, von Willebrand factor and its activity) which is significantly increased during an AE attack. All these markers must now be validated by prospective studies to determine their specificity and utility in diagnosis.

KEYWORDS:

C1 inhibitor; VE cadherin; biomarkers; endothelial dysfunction; hereditary angioedema; vascular permeability

PMID:
25905454
DOI:
10.1684/ejd.2015.2547
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for John Libbey Eurotext
Loading ...
Support Center